Development of a Stable Peptide-Major Histocompatibility Complex (MHC) via Sortase and Click Chemistry.


Journal

ACS pharmacology & translational science
ISSN: 2575-9108
Titre abrégé: ACS Pharmacol Transl Sci
Pays: United States
ID NLM: 101721411

Informations de publication

Date de publication:
14 Jun 2024
Historique:
received: 03 10 2023
revised: 14 04 2024
accepted: 16 04 2024
pmc-release: 24 05 2025
medline: 20 6 2024
pubmed: 20 6 2024
entrez: 20 6 2024
Statut: epublish

Résumé

T cells play a crucial role in antitumor immune responses and the clearance of infected cells. They identify their targets through the binding of T-cell receptors (TCRs) to peptide-major histocompatibility complex (pMHC) molecules present in cancer cells, infected cells, and antigen-presenting cells. This interaction is often weak, requiring multimeric pMHC molecules to enhance the avidity for identifying antigen-specific T cells. Current exchangeable pMHC-I tetramerization methods may overlook TCRs recognizing less stable yet immunogenic peptides.

Identifiants

pubmed: 38898944
doi: 10.1021/acsptsci.3c00268
pmc: PMC11184609
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1746-1757

Informations de copyright

© 2024 American Chemical Society.

Déclaration de conflit d'intérêts

The authors declare no competing financial interest.

Auteurs

Safak C Uslu (SC)

Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.
Medical Scientist Training Program, Hacettepe University Faculty of Medicine, Ankara 06230, Turkey.

Uk-Jae Lee (UJ)

Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.

Soheil Tavakolpour (S)

Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.

Omar Abousaway (O)

Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.

Ali Nili (A)

Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.

Lily Bass (L)

Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.

Pragallabh Purwar (P)

Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.

Edward Lacson (E)

Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.

Lea Berland (L)

Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.
CNRS, INSERM, IRCAN, Université Côte d'Azur, 06100 Nice, France.

Adrien Kuhnast (A)

Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.

Louise M Clark (LM)

Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.

Delia Picard (D)

Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.

Taha Rakhshandehroo (T)

Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.

Shreya R Mantri (SR)

Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.

Heydar Moravej (H)

Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.

Mohammad Rashidian (M)

Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.
Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02215, United States.
Parker Institute for Cancer Immunotherapy, San Francisco, California 94129, United States.

Classifications MeSH